$3.69
+0.04 (+1.10%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IRD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 9 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Squarepoint Ops LLC, +4 more) · FINRA short interest 11.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)NCT07681778Number of dose-limiting toxicity (DLT) events at the proposed dosesOpen-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: OPGx-RDH12 | Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA) | 10 | Dec 2032 | ≤ 2,326 d | 2026-07-15 |
| Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)NCT07185256Number of dose-limiting toxicity (DLT) events at the dose testedOpen-label · Treatment | Phase 1/2 | Recruiting | Genetic: OPGx-BEST1 | ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy | 10 | Aug 2030 | ≤ 1,473 d | 2026-03-24 |
| Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated PatientsNCT05616793Incidence of Dose Limiting ToxicitiesNon-randomized · Open-label · Other | Phase 1/2 | Recruiting | Biological: AAV8.hLCA5 | LCA5 | 22 | 2028-06-15 | in 666 d | 2026-02-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19